Will neurologists start ordering weight loss drugs?
The U.S. Food and Drug Administration approved Novo Nordisk’s (NOVOb.CO), opens new tabweight-loss drug Wegovy on Friday for lowering the risk of stroke and heart attack in overweight or obese adults who do not have diabetes.
Novo’s widely used diabetes drug Ozempic and weight-loss drug Wegovy, both chemically known as semaglutide, belong to a class of drugs called GLP-1 agonists. Originally developed for type 2 diabetes, they also reduce food cravings and cause the stomach to empty more slowly.
CNMRI: Neurology, Sleep Medicine, MRI 